XML 30 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Revenues
 6 Months Ended
Jun. 30, 2020
Segment Reporting [Abstract]  
REVENUES REVENUES
Product Revenues
The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018.
The Company’s net revenues consisted of the following for the three and six months ended June 30, 2020 and 2019:
Three months ended June 30,Six months ended June 30,
2020201920202019
Products:
Acetadote$595,310  $983,473  $1,308,711  $1,832,976  
Omeclamox-Pak10,948  478,604  124,371  678,141  
Kristalose3,477,471  3,476,807  6,771,433  6,785,050  
Vaprisol174,159  212,526  382,016  499,202  
Caldolor1,166,569  1,054,718  2,261,286  2,372,599  
Vibativ3,299,507  2,599,280  5,721,708  4,659,471  
Other revenue874,213  612,035  1,359,386  1,319,864  
Total net revenues$9,598,177  $9,417,443  $17,928,911  $18,147,303  

Other Revenues
The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner’s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies. The contractual payments associated with the partner’s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.
Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET’s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.1 million and $0.2 million for the three months ended June 30, 2020 and 2019, and $0.3 million and $0.8 million for the six months ended June 30, 2020 and 2019, respectively.